“The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,” said Stéphane Bancel, Chief Executive Officer of ...
Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease CAMBRIDGE, MA / ACCESS Newswire / July 10, 2025 / ...
The Food and Drug Administration is delaying a decision on authorizing Moderna Inc.’s MRNA -1.69% COVID-19 vaccine for adolescents to assess whether the shot may lead to heightened risk of a rare ...
CHICAGO -- Moderna announced interim results of its Covid-19 vaccine for children younger than 6 on Wednesday. The company said two 25-microgram doses of its Covid-19 vaccine for children ages 6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results